Roxane Laboratories, Inc.

Roxane Laboratories, Inc. — also shortened to Roxane — was a U.S. generic and specialty pharmaceutical manufacturer headquartered at 1809 Wilson Road, Columbus, Ohio. Its predecessor, Columbus Pharmacal, dates to 1885; the business was renamed Philips Roxane after a 1959 acquisition by Philips and became Roxane Laboratories after Boehringer Ingelheim acquired it in 1978. Until 2016 it operated as a subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT). Press accounts and a Hikma acquisition prospectus describe a c. 875,000 sq-ft Columbus manufacturing/R&D site and roughly 1,000–1,360 employees. In February 2016 Hikma Pharmaceuticals PLC acquired Roxane for approximately $2.65 billion ($2.1 billion net, cash plus stock), folding it into its U.S. West-Ward business; the legal entity became Hikma Labs Inc. and the Columbus site became West-Ward Columbus.

Products / operations. Roxane was an operating company, not an NPE. It developed and sold generic (multisource) prescription drugs under ANDAs, plus some NDAs, spanning immediate-release and controlled-release oral solids, oral liquids and unit-dose liquids, nasal sprays, cytotoxics, dry-powder inhalers, high-potency compounds, and DEA Schedule II–V controlled substances (e.g., morphine sulfate, zaleplon). Its customers were wholesalers, retail chains, and group purchasing organizations, with essentially all revenue from the U.S. market.

Litigation posture. The tracked data show 13 cases as defendant and 3 as plaintiff — the profile of an operating generics manufacturer sued by brand-name patent holders over ANDA/Paragraph IV filings, most notably Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc. (D.N.J., from 2010 onward) concerning sodium oxybate (Xyrem). Roxane also appeared as a petitioner/plaintiff at the PTAB in 2014 (Roxane v. Jazz), typical of ANDA defendants challenging Orange Book patents. Its suits cluster in the District of New Jersey rather than plaintiff-friendly Texas venues.

Notable context. The 2020 New York State Teamsters Council Health & Hospital Fund v. Jazz Pharmaceuticals cases (N.D. Cal.) are follow-on antitrust/monopolization actions tied to Xyrem, in which Roxane's successor entities were named. Post-2016, ownership of several Roxane ANDAs (e.g., iloperidone) was transferred to West-Ward/Hikma subsidiaries.